Evidence map›Paper›PMID 42079170›Full record

ArticlebioRxiv : the preprint server for biology2026

Phosphorylated ubiquitin is a secondary messenger and an epigenetic mark mediating mitochondria to nucleus signaling.

Thomas J Mercer, Bence Daniel, Craig Fredrickson, Daniel Le, Serena Lee, Vineet Vinay Kulkarni, Xu Hou, Fabienne C Fiesel, Hai Ngu, Min Jung and 12 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Thomas J MercerProteomic and Genomic Technologies, Genentech, South San Francisco, USA.
Bence DanielProteomic and Genomic Technologies, Genentech, South San Francisco, USA.ORCID 0000-0002-2410-8767
Craig FredricksonNeuroscience Department, Genentech, South San Francisco, USA.
Daniel LeProteomic and Genomic Technologies, Genentech, South San Francisco, USA.
Serena LeeResearch Pathology, Genentech, South San Francisco, USA.
Vineet Vinay KulkarniNeuroscience Department, Genentech, South San Francisco, USA.
Xu HouDepartment of Neuroscience, Mayo Clinic, Jacksonville, USA.ORCID 0000-0003-3011-4378
Fabienne C FieselDepartment of Neuroscience, Mayo Clinic, Jacksonville, USA.ORCID 0000-0002-1919-9676
Hai NguResearch Pathology, Genentech, South San Francisco, USA.
Min JungNeuroscience Department, Genentech, South San Francisco, USA.
Brent J RyanOxford Parkinson's Disease Centre and Department of Physiology, University of Oxford, Oxford, UK.ORCID 0000-0002-6703-3718
Rachel Heon-RobertsOxford Parkinson's Disease Centre and Department of Physiology, University of Oxford, Oxford, UK.
Amelia J SmithOxford Parkinson's Disease Centre and Department of Physiology, University of Oxford, Oxford, UK.
Vasumathi KameswaranProteomic and Genomic Technologies, Genentech, South San Francisco, USA.
Tommy K CheungProteomic and Genomic Technologies, Genentech, South San Francisco, USA.
Denise GastaldoNeuroscience Department, Genentech, South San Francisco, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, USA.ORCID 0000-0001-7189-7917
Wolfdieter SpringerDepartment of Neuroscience, Mayo Clinic, Jacksonville, USA.
Claire JeongNeuroscience Department, Genentech, South San Francisco, USA.
Oded ForemanResearch Pathology, Genentech, South San Francisco, USA.
Christopher M RoseProteomic and Genomic Technologies, Genentech, South San Francisco, USA.
Baris BingolNeuroscience Department, Genentech, South San Francisco, USA.

Funding

Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J · 2019 to 2023
$14.5M
Molecular mechanisms of PINK1-PRKN directed mitochondrial quality controlRF1NS085070 · NINDS · MAYO CLINIC JACKSONVILLE · PI SPRINGER, WOLFDIETER · 2019 to 2019
$2.8M
Mitochondrial Sirtuin 3 in Parkinson's diseaseR01NS110085 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J, SPRINGER, WOLFDIETER · 2019 to 2023
$2.5M
NINDS NIH HHS R01 NS110085NINDS NIH HHS RF1 NS085070NINDS NIH HHS U54 NS110435
6 · The paper itself

Abstract

Parkinson's disease (PD) is commonly associated with dysfunctional mitochondrial homeostasis. PINK1, a S/T kinase mutated in early-onset PD, generates phosphoserine 65 ubiquitin (pS65Ub) on damaged mitochondria facilitating their removal. Here, we show that pS65Ub translocates into the nucleus after generation at damaged mitochondria and is directly attached to substrates by resident E3 ligases. Histone H2A is a major substrate and is modified at lysine 119 (H2AK119) by the polycomb silencer, E3 ligase RING1B. At nucleosomes, pS65Ub simultaneously suppresses RING1B and potentiates H2A deubiquitinases USP16 and USP21. Epigenetic profiling and RNA sequencing reveal that pS65Ub is enriched at the promoters of poorly expressed yet dynamically regulated genes and is associated with H2AK119ub depletion. Functionally, we show that pS65Ub enrichment drives polycomb target gene expression, which accelerates the maturation of dopaminergic neurons. Importantly, post-mortem PD brains exhibit elevated nuclear pS65Ub, potentially linking nuclear pS65Ub accumulation with disease pathogenesis. Together, these data indicate that pS65Ub generated at damaged mitochondria regulates fundamental cellular processes at distant sites.

Identifiers

PMID42079170
PMCPMC13131604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.